BI
BIOC.EGX Glaxo Smith Kline
290.70 EGP
Close of Oct 29, 2026
58.03
550.00
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is BIOC.EGX undervalued?
Graham numberThe Graham number of Glaxo Smith Kline cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Glaxo Smith Kline fundamental analysis
No fundamental analysis for Glaxo Smith Kline yet.
Glaxo Smith Kline stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
Financial statements of Glaxo Smith Kline are not available yet.
Glaxo Smith Kline dividends
Glaxo Smith Kline has not paid dividends in the last 1 fiscal years.
Who owns Glaxo Smith Kline
Ownership data of Glaxo Smith Kline is not available yet.
Glaxo Smith Kline company profile
- Company name
- Glaxo Smith Kline
- Ticker
- BIOC.EGX
- ISIN
- EGS38171C012
- Exchange
- Egyptian Exchange
- Sector
- -
- Industry
- -
- Address
- Website
- -